Experimental Treatment for Patients with Lymphoma
common.study.values.description
“PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)”
This study will evaluate the safety, tolerability, and efficacy of oral KPT-9274 for the treatment of patients with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - KPT-9274
Drug - KPT-9274 & Niacin ER
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
common.study.values.clinical-trial-id
NCT02702492
participant.views.study.view.id
DbDEkd
